Skip to Content

Newsletter No. 89 -- November 2006

Newsletter No. 89 -- November 2006

NIH - Announcements

Change in Standing Receipt Dates for NIH/AHRQ/NIOSH Beginning in January 2007 (NOT-OD-07-001)

Request for Information (RFI): Possible Page Limit Reduction For the Research Plan Section of the Research Project Grant (R01) Application (NOT-OD-07-014)
Replies accepted until: January 5, 2007

Request for Information (RFI): To Solicit Input and Ideas for Roadmap Trans-NIH Strategic Initiatives (NOT-OD-07-011)
Replies due: no later than November 17, 2006
The NIH is seeking input from the scientific community, health professionals, patient advocates, and the general public about innovative and cross - cutting initiatives that will improve and accelerate biomedical research and its impact on the health of the Nation. Collecting these ideas is an initial step in the process of identifying a new cohort of "Roadmap" trans - NIH strategic initiatives for Fiscal Year 2008.

Request for Information (RFI): Resources for Optimizing Use of PET Radiotracers (NOT-DA-07-004) (NIDA)
Replies due: no later than November 21, 2006
This Request for Information is a time-sensitive request to the positron emission tomography (PET) community directed toward determining some specific aspects related to better utilization of PET radiopharmaceutical imaging agents across centers. Based on the response from this inquiry, the NIH is considering initiatives to enhance the use of PET radiotracers beyond single disease applications to promote their use in multiple diseases as well as to increase collaborative efforts between sites.

NIH Regional Seminars in Program Funding & Grants Administration
March 2007: Salt Lake City; April 2007: Research Triangle, NC

Notice of Intent to Publish a Request for Applications (RFA) for National Institute of Biomedical Imaging and Bioengineering (NIBIB) Quantum Projects: Exploratory Phase I (NOT-EB-07-001)

NIH - New Funding Initiatives

Small Business Innovation Research (SBIR) Program Contract Solicitation Now Available (NOT-OD-06-091) (NIH)

Image-Guided Cancer Interventions (STTR [R41/R42]) (PA-07-041) (NCI)
Image-Guided Cancer Interventions (SBIR [R43/R44]) (PA-07-042) (NCI)
Application Receipt/Submission Date(s): Multiple dates, see announcements.
This Funding Opportunity Announcement (FOA) supports the development and clinical validation of systems for image-guided interventions (IGIs) for cancer.

2007 NIH Director's Pioneer Award Program (DP1) (RFA-RM-07-005) (NIH Roadmap Initiatives)
Application Receipt Date(s): January 16, 2007
The National Institutes of Health (NIH) is engaged in a series of initiatives, collectively known as the "NIH Roadmap for Medical Research" (, which promote clinical and translational investigation and aim to improve health and prevent disease. The NIH Director's Pioneer Award Program, is a High-Risk Research initiative of Research Teams of the Future. The term "pioneering" is used to describe highly innovative approaches that have the potential to produce an unusually high impact, and the term "award" is used to mean a grant for conducting research, rather than a reward for past achievements. This Funding Opportunity Announcement (FOA) will utilize the DP1 grant mechanism.

Innovations in Biomedical Computational Science and Technology (R01) (PAR-06-410) (NIH - some ICs)
Exploratory Innovations in Biomedical Computational Science and Technology (R21) (PAR-06-411) (NIH - some ICs)
The NIH is interested in promoting research and developments in computational science and technology that will support rapid progress in areas of scientific opportunity in biomedical research. As defined here, biomedical computing or biomedical information science and technology includes database design, graphical interfaces, querying approaches, data retrieval, data visualization and manipulation, data integration through the development of integrated analytical tools, and tools for electronic collaboration, as well as computational and mathematical research including the development of structural, functional, integrative, and analytical models and simulations.
URL for R01:
URL for R21:

Bioengineering Approaches to Energy Balance and Obesity (R21) (RFA-HL-07-007)
Letter of Intent Due: November 24, 2006
Application Receipt Date(s): December 22, 2006
The institutes are soliciting applications to develop and validate new and innovative engineering approaches to address clinical problems related to energy balance, intake, and expenditure. Novel sensors, devices, imaging, and other technologies, including technologies to detect biochemical markers of energy balance, are expected to be developed and evaluated by collaborating engineers, physical scientists, mathematicians, and scientists from other relevant disciplines with expertise in obesity and nutrition.

Functional Links between the Immune System, Brain Function and Behavior (R21)
Application Receipt/Submission Date(s): Multiple dates, see announcement.
The potent effects of neuroimmune molecules in the brain are mediated through multiple signaling pathways. However, details regarding the extent, routes, or mechanisms whereby immune signaling affects the brain in either normal conditions or during immune challenge and inflammation are largely unexplored. The purpose of this FOA is to identify research opportunities that may help to bridge the gap in understanding how immune cells and their mediators affect brain development, function and behaviors related to cognition and mood.

Notice of Availability of Funds to Support Clinical trials on the Safety and Effectiveness of Products for Rare Diseases (NOT-FD-06-001) (FDA)
Next receipt date: February 7, 2007
The Food and Drug Administration's (FDA) Office of Orphan Products Development (OPD) is pleased to announce the availability of funds for fiscal year (FY) 2008 grant awards to support clinical trials on the safety and effectiveness of products for rare diseases and conditions.

Cancer Education Grants Program (R25) (PAR-06-540)( NCI)
Application Receipt/Submission Date(s): Multiple dates, see announcement.
The R25 grant mechanism is being used to support the following types of programs: innovative educational programs intended to motivate biomedical and other health science students to pursue cancer related careers; short courses to update cancer research scientists in new scientific methods, technologies and findings; training of cancer care clinicians and community health care providers in evidence-based cancer prevention and control approaches; development of effective innovative education (dissemination) approaches to translate knowledge gained from science (discovery) into public health and community applications (delivery).

Mentored Clinical Scientist Research Career Development Award (K08) (PA-06-512) (NIH - some ICs)
Application Receipt/Submission Date(s): Multiple dates, see announcement.
The Mentored Clinical Scientist Research Career Development Award (K08) represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research.

Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R21) (PA-06-461) (NIMH, NIA, NIAAA, NIBIB, NIDA, NINDS)
Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R33) (PA-06-462) (NIMH, NIA, NIAAA, NIBIB, NIDA, NINDS)
Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (Phased Innovation Award [R21/R33]) (PA-06-463) (NIMH, NIA, NIAAA, NIBIB, NIDA, NINDS)
Application Receipt/Submission Date(s): Multiple dates, see announcement.
The ICs invite applications that propose the development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in human brain, and that incorporate pilot or clinical feasibility evaluation in pre-clinical studies, model development, or clinical studies.
URL for R21:
URL for R33:
URL for R21/R33:

American Association of Physicists in Medicine Support for Clinical Residency in Imaging
Application submission date: February 1, 2007
One $36,000 award granted to one institution for support of a clinical residency in medical physics (imaging). The grant of $18,000 per year is granted to an approved institution in partial support of a full-time clinical residency. It is the policy of the AAPM that none of the funds may be budgeted to Facilities and Administrative Costs.

Charlotte Geyer Foundation Interim Funding
Next submission deadline: February 1, 2007
For researchers whose proposals have been reviewed by the National Cancer Institute and were ranked within ten percentage points of the NCI payline.


Extramural Loan Repayment Program for Clinical Researchers (LRP) (PA-06-517) (NIH)
Application Receipt/Submission Date(s): September 1, 2006 - December 1, 2006, 8 P.M. EST

NIH Policy on Late Submission of Grant Applications (NOT-OD-06-086)

Clarification Of Eligibility For Mid-Career Investigator Award In Patient-Oriented Research (K24) (NOT-OD-06-095) (NIH)
Candidates for this award must be mid-career health-professional doctorates or equivalent and should be at the Associate Professor level or the equivalent. Applicants may request and may be awarded from three to five years of support.

CIP Cancer Tracer Synthesis Resources
The Cancer Imaging Program has been creating Investigational New Drug Applications (IND) for imaging agents in order to engage in multi-center clinical trials of these materials. A subset of the documents filed is being made available to the research community to implement routine synthesis of tracers at their own facilities and to assist investigators with the filing of their own INDs. The first of these document sets is for F-18 fluorothymidine (FLT).

NIH Extramural Nexus
The NIH Extramural Nexus is a bimonthly update from the NIH Office of Extramural Research (OER), NIH. The OER is the hub for grants policy and operations, grants administration, and the coordination of NIH's extramural programs and activities. See the issues.

The Cancer Imaging Program of the NCI requests submissions for its Development of Clinical Imaging Drugs and Enhancers (DCIDE) initiative. The goal is the rapid movement of promising, novel cancer imaging enhancers or molecular probes from the laboratory to proof of principle clinical trials. See the web site for details.

The NIH Commons web site allows all NIH grantee organizations to interact with grants data, to check the status of grant applications, including viewing scores and summary statements when they are ready, and to submit progress reports on line, among a number of functions. Applicants and grants administrators should become familiar with the Commons.


RSNA 2006
November 26 - December 1, 2006, McCormick Place, Chicago, IL
CIP 10th Anniversary Celebration Events:
Lecture Series on Cancer Imaging Clinical Trials, Image-Guided Intervention, and Quantification for Change Analysis
Lakeside Learning Center, Molecular Imaging Zone
Technical Exhibit in Hall A, South Building, Booth 1043

In Vivo Small Animal Imaging: An Introductory Workshop
December 11 - 12, 2006, U C Davis Genome and Biomedical Sciences Facility, Davis, CA

Seventh National Forum on Biomedical Imaging in Oncology: Oncologic Image-Guided Interventions: Opportunities for Collaboration
February 1-2, 2007, Bethesda North Marriott, Rockville, Maryland

17th International Symposium on Radiopharmaceutical Sciences
April 30 - May 4, 2007, Aachen, Germany

Society of Nuclear Medicine 54th Annual Scientific Meeting
June 2 - 6, 2007, Washington, DC

Molecular Imaging Joint Conference of the Academy of Molecular Imaging and the Society for Molecular Imaging
September 7 - 11, 2007, Providence, Rhode Island

The Cancer Imaging Program at NCI has created this e-mail distribution list to notify interested people about funding opportunities and other issues related to imaging research. Its primary purpose is to call your attention to important, relevant information on NIH Web pages, or in the NIH Guide. Occasionally it may be used to clarify areas of confusion, or disseminate answers to frequently asked questions.

If you wish to remain on the list, no action is necessary. If you wish to be added to the list, please contact Dr Barbara Croft by return e-mail ( Please include your complete mailing address, title, phone and fax numbers.

Cancer Imaging Program
Division of Cancer Treatment and Diagnosis, NCI
6130 Executive Boulevard - MSC-7412
Bethesda, MD 20892-7412
Tel: 301 496 9531
Fax: 301 480 3507